NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis $46.71 -0.69 (-1.46%) Closing price 03:59 PM EasternExtended Trading$46.58 -0.13 (-0.29%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About AnaptysBio Stock (NASDAQ:ANAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get AnaptysBio alerts:Sign Up Key Stats Today's Range$46.05▼$47.7150-Day Range$45.43▼$55.2052-Week Range$22.07▼$72.36Volume432,444 shsAverage Volume410,362 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/APrice Target$75.67Consensus RatingModerate Buy Company Overview AnaptysBio is a biotechnology company focused on developing antibody-based treatments for inflammatory and autoimmune diseases. Its research programs target immune pathways that may be involved in conditions with significant unmet medical needs. The company’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 pathway, and ANB032, an investigational antibody targeting BTLA. AnaptysBio has also developed imsidolimab, an antibody targeting the IL-36 receptor; global rights to that program were licensed to Vanda Pharmaceuticals. Founded in 2005 and based in San Diego, California, AnaptysBio also has a history of licensing antibody-discovery programs to other pharmaceutical companies. Its work includes collaborations that have contributed to medicines developed and commercialized by partners.AI Generated. May Contain Errors. Read More AnaptysBio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreANAB MarketRank™: 4.281391830555 of 5 starsAnaptysBio scored higher than 86% of companies evaluated by MarketBeat, and ranked 48th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialAnaptysBio has a consensus price target of $75.67, representing about 62.0% upside from its current price of $46.71.Amount of Analyst CoverageAnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about AnaptysBio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is 9.42, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.29.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is 9.42, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.47.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 66.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.66% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 10.79, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently decreased by 6.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.16 News SentimentAnaptysBio has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for AnaptysBio this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for ANAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $16,975,495.00 in company stock, which represents 1.2224% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have bought 6,807.90% more of their company's stock than they have sold. Specifically, they have bought $17,224,845.00 in company stock and sold $249,350.00 in company stock.Percentage Held by Insiders31.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAnaptysBio has minimal institutional ownership at this time.Read more about AnaptysBio's insider trading history. Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANAB Stock News HeadlinesAnaptysBio (NASDAQ:ANAB) Stock: Insider Ecor1 Capital, Llc Acquires 152,367 SharesNovember 20 at 4:10 AM | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Stock: Insider Ecor1 Capital, Llc Purchases 138,093 SharesNovember 20 at 4:10 AM | americanbankingnews.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 20 at 1:00 AM | Base Camp Trading (Ad)AnaptysBio (NASDAQ:ANAB) Stock: Insider Ecor1 Capital, Llc Buys 84,120 SharesNovember 19 at 6:22 AM | insidertrades.comWhat is HC Wainwright's Estimate for AnaptysBio Q2 Earnings?November 19 at 2:13 AM | americanbankingnews.comAnaptysBio, Inc. (ANAB) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17 at 10:16 PM | seekingalpha.comTranscript : AnaptysBio, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 04:40 PMNovember 17 at 5:15 PM | marketscreener.comMAnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2026November 12, 2026 | marketscreener.comMSee More Headlines ANAB Stock Analysis - Frequently Asked Questions How have ANAB shares performed this year? AnaptysBio's stock was trading at $48.48 at the start of the year. Since then, ANAB stock has decreased by 3.7% and is now trading at $46.71. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings data on Thursday, November, 12th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.84) by $1.95. The biotechnology company had revenue of $30.27 million for the quarter, compared to analyst estimates of $25.56 million. AnaptysBio had a negative trailing twelve-month return on equity of 17.54% and a net margin of 96.30%. Is AnaptysBio buying back stock? AnaptysBio's Board of Directors initiated a share repurchase plan on Friday, March 27th 2026, which authorizes the company to repurchase $100 million in shares, according to EventVestor. This means that the company could repurchase up to 5.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its shares are undervalued. When did AnaptysBio IPO? AnaptysBio (ANAB) raised $75 million in an IPO on Thursday, January 26th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? Top institutional investors of AnaptysBio include State Street Corp (3.83%), Goldman Sachs Group Inc. (2.84%), Apis Capital Advisors LLC (1.49%) and First Trust Advisors LP (0.77%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, John P Schmid, Dennis Mulroy, Eric J Loumeau, Hollings Renton, Magda Marquet, J Anthony Ware and Dennis M Fenton. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include NVIDIA (NVDA), Tesla (TSLA), Shopify (SHOP), Advanced Micro Devices (AMD), Salesforce (CRM), Broadcom (AVGO) and FuelCell Energy (FCEL). Company Calendar Last Earnings11/12/2026Today11/20/202638th Annual Healthcare Conference12/02/20269th Annual Evercore ISI HealthCONx Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 8 days, ANAB's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANAB CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees104Year Founded2005Price Target and Rating Average Price Target for AnaptysBio$75.67 High Price Target$95.00 Low Price Target$50.00 Potential Upside/Downside+62.0%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)$4.96 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.23 million Net Margins96.30% Pretax Margin-21.60% Return on Equity-17.54% Return on Assets-1.08% Debt Debt-to-Equity Ratio0.17 Current Ratio8.40 Quick Ratio8.40 Sales & Book Value Annual Sales$234.60 million Price / Sales5.92 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book66.73Miscellaneous Outstanding Shares29,730,000Free Float20,365,000Market Cap$1.39 billion OptionableOptionable Beta0.70 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ANAB) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.